Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, March 25, 2014 /CNW/ - Cipher Pharmaceuticals Inc.
(TSX: DND) ("Cipher" or "the Company") today announced that Thomas G.
Wellner has been appointed to the Board of Directors of the Company.
Most recently, Mr. Wellner was co-CEO of LifeLabs, Canada's largest
laboratory services company, where he was responsible for leading the
integration of CML HealthCare into LifeLabs' organization. Prior to
LifeLabs, Mr. Wellner was President and Chief Executive Officer of CML
HealthCare, where he led the company through a strategic re-assessment
prior to the merger with LifeLabs. Before CML, he spent 20 years with
Eli Lilly & Company in a variety of senior operational and strategic
leadership roles in Canada, China, United States, Latin America,
Europe, and the United Kingdom. Mr. Wellner also served as CEO of
Therapure Biopharma from 2008 to 2011.
"We are very pleased to welcome Tom to Cipher's Board," said Gerry
McDole, Chair of Cipher. "Tom has a strong background in business
development, sales and marketing, and senior management in the
healthcare sector. His experience will be a valuable asset to Cipher as
the Company expands its product portfolio and operations in the coming
Mr. Wellner currently sits on the Boards of Diamedica (TSX:DMA),
Freshbooks (private) and Atlantic Healthcare (private). He is also a
Board member of Life Sciences Ontario. Mr. Wellner is a graduate of
Queen's University (B.Sc. Hons. Life Sciences).
As previously disclosed, Larry Andrews, President and CEO, will be
leaving Cipher. Accordingly, he will not stand for re-election to the
Company's Board of Directors. Mr. Andrews will remain with the Company
for a period of time while the Board undertakes a search process,
following which he will continue working with Cipher in a consulting
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND) is a growing specialty pharmaceutical
company with three commercial products and a fourth in development. Our
product candidates are typically improved formulations of successful,
currently marketed drugs. We in-license a product, manage the required
clinical development and regulatory approval process, and either
out-license it to a marketing partner, or, in Canada, we may market the
product ourselves. Our core capabilities are in clinical and regulatory
affairs, product licensing, supply chain management, and marketing and
sales. Since the Company was founded in 2000, we have achieved final
regulatory approval in the U.S. and Canada for all three of our
original products and completed six marketing partnerships, generating
growing licensing revenue.
SOURCE: Cipher Pharmaceuticals Inc.
For further information:
(416) 815-0700 ext 278
(416) 815-0080 fax
Chief Financial Officer
(905) 602-5840 ext 323
(905) 602-0628 fax